Form 4: Agios Pharmaceuticals Executive Tsveta Milanova Reports Stock Transactions

Tsveta Milanova, Chief Commercial Officer of Agios Pharmaceuticals, reports the acquisition and disposal of common stock related to restricted stock unit vesting.

Summary

• On January 3, 2025, Tsveta Milanova, Chief Commercial Officer of Agios Pharmaceuticals, acquired 8,476 shares of common stock through the vesting of restricted stock units.
• Also on January 3, 2025, 8,476 shares were disposed of.
• On January 6, 2025, Ms. Milanova sold 2,804 shares of common stock at a price of $32.18 per share.
• Following these transactions, Ms. Milanova directly owns 18,906 shares of Agios Pharmaceuticals common stock and 8,475 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions, with no inherent positive or negative sentiment. It reflects routine executive compensation activity.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry as part of executive compensation packages.

Comparison to Industry Standards

• Executive stock transactions are a standard part of compensation in publicly traded companies, including pharmaceutical firms like Agios.
• Similar filings are regularly made by executives at companies like Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD) when they exercise stock options or sell shares.
• The vesting schedule of restricted stock units, with annual installments, is a typical arrangement seen across the industry.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares in the open market.
• The vesting of restricted stock units incentivizes the executive, potentially aligning their interests with those of the shareholders.

Key Dates